News - Repligen, Nephrology and Hepatology

Filter

Popular Filters

1 to 25 of 89 results

Otsuka’s Samsca, first ADPKD therapy, approved in Japan

25-03-2014

Japanese drugmaker Otsuka Pharmaceutical says it has become the first company in the world to obtain…

Asia-PacificJapanNephrology and HepatologyOtsukaPharmaceuticalRegulationSamsca

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex

19-03-2014

German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly

18-03-2014

The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

Strong Ph III data on Intercept’s OCA, but shares hit by side effect concerns

Strong Ph III data on Intercept’s OCA, but shares hit by side effect concerns

17-03-2014

USA-based Intercept Pharmaceuticals reported positive Phase III results on its obeticholic acid (OCA)…

Intercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

13-03-2014

US biotech firm Islet Sciences says it has signed a binding letter of intent to acquire Brighthaven Ventures…

BiotechnologyDiabetesIslet SciencesMergers & AcquisitionsNephrology and Hepatologyremogliflozin

La Jolla’s shares soar as it reports positive results in kidney disease trial

12-03-2014

US-based La Jolla Pharmaceutical Company has announced positive top-line results from its randomized,…

La Jolla PharmaceuticalNephrology and HepatologyPharmaceuticalResearchUSA

Keryx Biopharma files for EU approval of Zerenex

Keryx Biopharma files for EU approval of Zerenex

10-03-2014

US drugmaker Keryx Biopharmaceuticals has submitted a Marketing Authorization Application to the European…

EuropeKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationZerenex

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

25-02-2014

US venture-funded biopharmaceutical company Ardelyx has licensed its novel phosphate transport NaP2b…

ArdelyxAstraZenecaLicensingNaP2bNephrology and HepatologyPharmaceuticalSanofitenapanor

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

29-01-2014

After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

FDA cites insufficient information in response to AMAG’s Feraheme application

FDA cites insufficient information in response to AMAG’s Feraheme application

23-01-2014

US drug company AMAG Pharmaceuticals (Nasdaq: AMAG) has received a complete response letter from the…

AMAG PharmaceuticalsFerahemeHematologyNephrology and HepatologyPharmaceuticalRegulationUSA

BioMarin buys rights to Repligen preclinical compounds

23-01-2014

BioMarin Pharmaceuticals has entered into an agreement to purchase from fellow USA-based Repligen Corp…

BioMarin PharmaceuticalBiotechnologyLicensingRare diseasesRepligen

Intercept rockets on positive liver disease drug trial

10-01-2014

Shares of USA-based Intercept Pharmaceuticals tripled to $275.87 by close of trading on January 9, when…

Dainippon Sumitomo PharmaIntercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

Italy’s Gentium accepts $1 billion takeover offer from Jazz Pharma

20-12-2013

Ireland-headquartered drugmaker Jazz Pharmaceuticals has entered into a definitive agreement to acquire…

defibrotideDefitelioGentiumItalyJazz PharmaceuticalsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalRare diseases

Velphoro receives US FDA approval for hyperphosphatemia in CKD

Velphoro receives US FDA approval for hyperphosphatemia in CKD

28-11-2013

Switzerland-based Vifor Pharma has received US Food and Drug Administration approval for Velphoro for…

Nephrology and HepatologyPharmaceuticalRegulationUSAVelphoroVifor Pharma

Avesthagen in deal with Elpen for biosimilar Aranesp in parts of Europe

21-11-2013

Avesthagen Pharma AG, a unit of India’s Avesthagen Ltd, has signed an agreement with Greek life sciences…

AmgenAranespAvdespAvesthagenBiosimilarsElpen PharmaceuticalsEuropeMarkets & MarketingNephrology and Hepatology

Bayer CEO calls for greater appreciation of innovation

Bayer CEO calls for greater appreciation of innovation

19-11-2013

Advances in cancer therapy are expected in the next years, thanks in particular to treatment using antibody-drug…

BayerNephrology and HepatologyOncologyPharmaceuticalResearchRespiratory and Pulmonary

Chronic kidney disease market to witness slight decline by 2017

Chronic kidney disease market to witness slight decline by 2017

12-11-2013

The value of the chronic kidney disease market could drop 2.5% between 2012 and 2017 due to the loss…

EuropeFinancialGenzymeMarkets & MarketingNephrology and HepatologyPharmaceuticalRenagelRenvelaUSAZemplar Capsules

Kyowa Hakko drops Ph II study of bardoxolone

11-11-2013

Japanese drugmaker Kyowa Hakko Kirin says it is discontinuing its Phase II clinical studies evaluating…

DiabetesKyowa Hakko KirinNephrology and HepatologyPharmaceuticalReata PharmaceuticalsResearch

US orphan status for Pharmalink’s Busulipo

US orphan status for Pharmalink’s Busulipo

29-10-2013

Swedish specialty pharma group Pharmalink says its product Busulipo, (busulfan), a best-in-class conditioning…

BusulipoNefeconNephrology and HepatologyNorth AmericaOncologyPharmaceuticalPharmaLinkRegulationResearch

Evolva to license EV-077 to Serodus

07-10-2013

Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

Otsuka's Samsca gains additional indication in Japan

17-09-2013

Japanese drugmaker Otsuka (TYO: 4768) says that its vasopressin V2 receptor antagonist Samsca (tolvaptan)…

Asia-PacificNephrology and HepatologyOtsukaPharmaceuticalRegulationSamscatolvaptan

Interim results for ChemoCentryx' CCX140 fail to inspire

12-09-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) announced interim data from an ongoing Phase II study in…

BiotechnologyCCX140ChemoCentryxDiabetesNephrology and HepatologyResearch

Scottish Medicines Consortium approves MabThera for vasculitis, Lyxumia for diabetes and Targaxan for liver disease

10-09-2013

Drug regulator the Scottish Medicines Consortium (SMC) has today approved the National Health Service…

DiabetesEuropeHealthcareLyxumiaMabTheraNephrology and HepatologyNorginePharmaceuticalRocheSanofiTargaxan

1 to 25 of 89 results

Company Spotlight

Fibrotech

Fibrotech

Back to top